Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Oral Maxillofac Surg ; 43(6): 511-2, 2005 Dec.
Article in English | MEDLINE | ID: mdl-15908082

ABSTRACT

In the UK the government introduced the 'two week rule' for head and neck cancer in December 2000, which sought to guarantee that any patient with suspected cancer would be seen by a specialist within 2 weeks of being referred. Our aim was to find out whether referral under the 'two week rule' resulted in patients being given an appointment and starting treatment faster than those who had been referred urgently directly to a consultant surgeon. A retrospective review of case notes of all patients diagnosed with oral cancer over a six-month period showed that only 3 of 22 were referred under the 'two week rule'. A total of 48 referrals under the 'two week rule' were recorded during the same period. There was no significant difference between the two groups in terms of time waiting for an outpatient appointment and time spent waiting for treatment.


Subject(s)
Mouth Neoplasms/diagnosis , Referral and Consultation , Surgery, Oral , Appointments and Schedules , Dental Service, Hospital/organization & administration , Guideline Adherence , Humans , Practice Guidelines as Topic , Retrospective Studies , Time Factors , United Kingdom
2.
J Clin Oncol ; 12(10): 2051-9, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7931473

ABSTRACT

PURPOSE: This phase II study was undertaken to assess the efficacy and toxicity of the addition of continuous low-dose interferon alfa-2a (IFN) to fludarabine in patients with advanced or refractory mycosis fungoides (MF) or the Sézary syndrome (SS). PATIENTS AND METHODS: Thirty-five patients were treated with fludarabine 25 mg/m2 intravenously (IV) on days 1 to 5 every 28 days along with IFN 5 x 10(6) U/m2 subcutaneously three times per week continuously for up to eight cycles. IFN doses were escalated to 7.5 x 10(6)/m2 at day 29 if constitutional toxicities were less than grade 3. Twenty-one patients had not responded to prior chemotherapy or total-skin electron-beam irradiation (TSEB), and 10 of these had received prior deoxycoformycin (pentostatin; DCF) and intermittent high-dose IFN; seven had received only topical therapies, and seven were untreated. RESULTS: Four patients achieved a complete response (CR) and 14 achieved a partial response (PR) for an overall response rate of 51% (95% confidence interval, 35% to 70%). Four of 11 patients with visceral involvement responded. The median progression-free survival duration of the patients who responded was 5.9 months, and three of the complete responders are in unmaintained response after 18 to 35 months. Grade 3 or 4 hematologic toxicity occurred in 21 patients, including two who developed persistent bone marrow aplasia. Eighteen patients developed infections during therapy, including five with herpes zoster, one with Pneumocystis carinii, one with extrapulmonary tuberculosis, and two with disseminated toxoplasmosis. CONCLUSION: The combination of fludarabine with continuous low-dose IFN is an active regimen in patients with advanced MF/SS, including patients with visceral involvement and patients who progressed after prior therapy with DCF and IFN. This regimen has induced unmaintained remissions in a small subset of patients.


Subject(s)
Antineoplastic Agents/administration & dosage , Interferon-alpha/administration & dosage , Mycosis Fungoides/therapy , Sezary Syndrome/therapy , Skin Neoplasms/therapy , Vidarabine/analogs & derivatives , Adult , Aged , Combined Modality Therapy , Disease-Free Survival , Drug Administration Schedule , Female , Humans , Interferon alpha-2 , Male , Middle Aged , Mycosis Fungoides/drug therapy , Recombinant Proteins , Remission Induction , Sezary Syndrome/drug therapy , Skin Neoplasms/drug therapy , Vidarabine/administration & dosage
3.
Blood ; 79(12): 3293-9, 1992 Jun 15.
Article in English | MEDLINE | ID: mdl-1596570

ABSTRACT

We investigated the correlation between the detection of clonal rearrangement of the T-cell antigen receptor gene (TCRR) in lymph node tissue with histopathologic lymph node classification in 33 patients with mycosis fungoides with and without the Sezary Syndrome. We analyzed DNA extracted from lymph nodes that were histologically uninvolved (LN1-2), dermatopathic nodes with clusters of atypical cells (LN3), and nodes effaced with lymphoma (LN4) and found TCRR in none of five LN1-2 nodes, 8 of 17 LN3 nodes, and 10 of 11 LN4 nodes. Further, the detection of TCRR correlated with presence of palpable adenopathy (P2 less than .0001) and was associated with a worse survival (P2 = .0024). Within the subgroup of patients with LN3 nodes, there was a trend (P2 = .14) toward inferior survival if nodes were involved by TCRR, irrespective of extent of skin disease. We conclude that detection of TCRR in nodes from mycosis fungoides patients is an objective and reliable means of assessing tumor infiltration of lymph node and is associated with an inferior survival.


Subject(s)
Gene Rearrangement, T-Lymphocyte , Lymph Nodes/pathology , Mycosis Fungoides/immunology , Skin Neoplasms/immunology , Blotting, Southern , Humans , Mycosis Fungoides/mortality , Mycosis Fungoides/pathology , Prognosis , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Survival Rate
4.
J Clin Oncol ; 8(1): 155-60, 1990 Jan.
Article in English | MEDLINE | ID: mdl-2295906

ABSTRACT

We previously demonstrated that recombinant interferon alfa-2a (IFN-alfa) in a dose of 50 X 10(6) U million units (MU)/m2 intramuscularly (IM) three times per week has efficacy against mycosis fungoides (MF) and the Sézary syndrome (SS). However, this regimen given to patients with refractory disease was uniformly complicated by toxicities requiring major dose reductions. The present study was designed to determine if intermittent high-dose IFN-alfa would preserve efficacy and decrease toxicity in a similar patient population. Twenty-four patients with advanced disease refractory to one or more standard therapies received IFN-alfa, 10 MU/m2 IM on day 1 followed by 50 MU/m2 IM on days 2 to 5 every 3 weeks; after the first four cycles, stable and partially responding patients underwent dose escalation to twice the starting dose. One complete (CR) and six partial responses (PRs) were observed (response rate, 29%; 95% confidence interval, 13% to 51%) lasting 4 to 19 months (median, 8 months). No improvement in objective response was seen in the eight patients who received dose escalation. Dose reductions were necessary in eight of 22 patients receiving one or more cycles of therapy. Weighted mean dose rate intensity for patients on this study over the first four cycles of treatment was 65.5 MU/m2/wk compared with 73.2 MU/m2/wk over the first 12 weeks of treatment in patients from the previous study, in which all 19 patients receiving more than 1 week of treatment required dose reduction. IFN-alfa is effective against previously treated MF and the SS and is better tolerated on this intermittent schedule.


Subject(s)
Interferon Type I/administration & dosage , Interferon-alpha/administration & dosage , Mycosis Fungoides/drug therapy , Sezary Syndrome/drug therapy , Skin Neoplasms/drug therapy , Combined Modality Therapy , Dose-Response Relationship, Drug , Drug Evaluation , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Mycosis Fungoides/mortality , Recombinant Proteins , Remission Induction , Sezary Syndrome/mortality , Skin Neoplasms/mortality , Time Factors
5.
N Engl J Med ; 321(26): 1784-90, 1989 Dec 28.
Article in English | MEDLINE | ID: mdl-2594037

ABSTRACT

Mycosis fungoides is a T-cell lymphoma that arises in the skin and progresses at highly variable rates. Nonradomized studies have suggested that early aggressive therapy may improve the prognosis in this usually fatal disease. We studied 103 patients with mycosis fungoides, who, after complete staging, were randomly assigned to receive either combination therapy, consisting of 3000 cGy of electron-beam radiation to the skin combined with parenteral chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine (n = 52) or sequential topical treatment (n = 51). The prognostic factors were well balanced in the two groups. Combined therapy produced considerable toxicity: 12 patients required hospitalization for fever and transient neutropenia, 5 had congestive heart failure, and 2 were later found to have acute nonlymphocytic leukemia. Patients receiving combined therapy had a significantly higher rate of complete response, documented by biopsy, than patients receiving conservative therapy (38 percent vs. 18 percent; P = 0.032). After a median follow-up of 75 months, however, there was no significant difference between the treatment groups in disease-free or overall survival. We conclude that early aggressive therapy with radiation and chemotherapy does not improve the prognosis for patients with mycosis fungoides as compared with conservative treatment beginning with sequential topical therapies.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Mycosis Fungoides/therapy , Skin Neoplasms/therapy , Combined Modality Therapy/adverse effects , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Electrons , Etoposide/administration & dosage , Female , Humans , Male , Middle Aged , Mycosis Fungoides/pathology , Neoplasm Staging , Radiotherapy Dosage , Random Allocation , Skin Neoplasms/pathology , Vincristine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...